The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.

Two stories of how, together with our industry partners and patients, Providence is working to make the latest trials available to more people who could benefit from them.

Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.

When the SpaceX mission returns to earth in April, there will be 80 mice onboard who have spent a month living at the International Space Station. The rodents represent the first investigational ophth

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.

A recent article in TIME magazine features research conducted by CORE and the Providence Research Network into the condition known as long COVID.

Four patients are among first in the nation to undergo groundbreaking pulsed field ablation procedure.

The FDA just approved a new immunotherapy for advanced melanoma. Dr. Walter Urba shares how Providence’s participation in the clinical study shows our standing as a global leader in immuno-oncology.

Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.

The Food and Drug Administration has approved an adoptive cell therapy for adult patients with melanoma that has spread to other parts of the body (metastatic).

Anchorage Fire Department, Providence Alaska Medical Center and Alaska Cardiovascular Research Foundation to collaborate on study of a new medication for treating patients experiencing a heart attack.

Learn about the latest findings and treatments for post-COVID syndrome from Providence.

A recent Providence study revealed that integrating a dynamic EMR order set results in improved adherence to established guidelines associated with reduction in early onset GBS neonatal sepsis.

A data analysis initiative supported by Providence CORE could significantly influence behavioral health policy and response strategies in Portland, Oregon, and statewide.

Research by Providence CORE offers insights to help healthcare organizations partner with patients to improve outcomes through genetic testing.

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy

A study led by Providence researcher Katherine Tuttle, MD, FACP, of Spokane, Washington is in the news thanks to findings around a promising new treatment for kidney disease.

New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.